AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cyclopentolate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 757 | 512-15-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K7,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK,TGFBR1 | 29 | |||
| kinase-selectivity-class | AXL,PDK4 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 31, 1974 | FDA | ALCON LABS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Corneal oedema | 126.00 | 46.20 | 22 | 1247 | 1879 | 90625299 |
| Toxic anterior segment syndrome | 109.26 | 46.20 | 20 | 1249 | 2230 | 90624948 |
| Keratopathy | 94.93 | 46.20 | 15 | 1254 | 693 | 90626485 |
| Corneal epithelium defect | 85.16 | 46.20 | 13 | 1256 | 478 | 90626700 |
| Anterior chamber cell | 79.90 | 46.20 | 13 | 1256 | 723 | 90626455 |
| Punctate keratitis | 71.85 | 46.20 | 12 | 1257 | 784 | 90626394 |
| Eye pain | 57.37 | 46.20 | 22 | 1247 | 44146 | 90583032 |
| Endophthalmitis | 55.89 | 46.20 | 13 | 1256 | 4672 | 90622506 |
| Visual acuity reduced | 54.56 | 46.20 | 18 | 1251 | 23392 | 90603786 |
| Iridocyclitis | 53.58 | 46.20 | 12 | 1257 | 3649 | 90623529 |
| Floppy iris syndrome | 51.25 | 46.20 | 7 | 1262 | 115 | 90627063 |
| Retinal detachment | 51.04 | 46.20 | 13 | 1256 | 6809 | 90620369 |
| Hypopyon | 50.05 | 46.20 | 9 | 1260 | 905 | 90626273 |
| Mydriasis | 49.31 | 46.20 | 15 | 1254 | 14997 | 90612181 |
| Presyncope | 49.16 | 46.20 | 18 | 1251 | 31787 | 90595391 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mydriasis | 59.35 | 40.22 | 16 | 699 | 8754 | 42611866 |
| Scleromalacia | 56.53 | 40.22 | 7 | 708 | 41 | 42620579 |
| Toxic anterior segment syndrome | 50.52 | 40.22 | 10 | 705 | 1406 | 42619214 |
| Corneal opacity | 44.66 | 40.22 | 8 | 707 | 657 | 42619963 |
| Keratopathy | 44.27 | 40.22 | 8 | 707 | 690 | 42619930 |
| Corneal epithelium defect | 41.32 | 40.22 | 7 | 708 | 415 | 42620205 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic anterior segment syndrome | 149.79 | 36.89 | 29 | 1941 | 3425 | 110583904 |
| Keratopathy | 134.62 | 36.89 | 23 | 1947 | 1350 | 110585979 |
| Corneal oedema | 133.64 | 36.89 | 26 | 1944 | 3147 | 110584182 |
| Corneal epithelium defect | 122.43 | 36.89 | 20 | 1950 | 892 | 110586437 |
| Anterior chamber cell | 96.34 | 36.89 | 17 | 1953 | 1204 | 110586125 |
| Punctate keratitis | 89.92 | 36.89 | 16 | 1954 | 1188 | 110586141 |
| Mydriasis | 87.66 | 36.89 | 27 | 1943 | 22130 | 110565199 |
| Eye pain | 83.68 | 36.89 | 32 | 1938 | 50067 | 110537262 |
| Visual acuity reduced | 73.92 | 36.89 | 26 | 1944 | 32147 | 110555182 |
| Endophthalmitis | 73.76 | 36.89 | 19 | 1951 | 8168 | 110579161 |
| Corneal opacity | 69.86 | 36.89 | 13 | 1957 | 1238 | 110586091 |
| Ocular hyperaemia | 58.15 | 36.89 | 23 | 1947 | 39263 | 110548066 |
| Iridocyclitis | 55.85 | 36.89 | 14 | 1956 | 5394 | 110581935 |
| Vision blurred | 54.80 | 36.89 | 32 | 1938 | 128990 | 110458339 |
| Uveitis | 51.59 | 36.89 | 18 | 1952 | 21692 | 110565637 |
| Intraocular pressure increased | 50.49 | 36.89 | 15 | 1955 | 10861 | 110576468 |
| Hypopyon | 49.71 | 36.89 | 10 | 1960 | 1430 | 110585899 |
| Scleromalacia | 43.12 | 36.89 | 6 | 1964 | 88 | 110587241 |
| Retinal detachment | 41.66 | 36.89 | 13 | 1957 | 11087 | 110576242 |
| Eye irritation | 40.63 | 36.89 | 17 | 1953 | 33435 | 110553894 |
| Corneal abrasion | 38.16 | 36.89 | 8 | 1962 | 1401 | 110585928 |
| Presyncope | 37.46 | 36.89 | 18 | 1952 | 48869 | 110538460 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01FA04 | SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics |
| ATC | S01FA54 | SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics |
| MeSH PA | D009184 | Mydriatics |
| MeSH PA | D010276 | Parasympatholytics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018727 | Muscarinic Antagonists |
| CHEBI has role | CHEBI:33295 | diagnostic agent |
| CHEBI has role | CHEBI:48876 | muscarinic antagonist |
| CHEBI has role | CHEBI:50370 | parasympatholytic |
| CHEBI has role | CHEBI:50513 | mydriatic agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
Related Drugs by ATC class:
S01FA Anticholinergics 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dilated pupil | indication | 37125009 | |
| Cycloplegia | indication | 68158006 | DOID:10033 |
| Perioperative Mydriasis | indication | ||
| Uveitis | off-label use | 128473001 | DOID:13141 |
| Prevention of Posterior Synechiae | off-label use | ||
| Brain damage | contraindication | 2470005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Spastic paralysis | contraindication | 78403003 | |
| Arterial aneurysm | contraindication | 233981004 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Predisposition to Glaucoma | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019700 | VUID |
| N0000147792 | NUI |
| D01002 | KEGG_DRUG |
| 5870-29-1 | SECONDARY_CAS_RN |
| 106029 | RXNORM |
| C0010582 | UMLSCUI |
| CHEBI:4024 | CHEBI |
| CHEMBL1201338 | ChEMBL_ID |
| CHEMBL1200473 | ChEMBL_ID |
| DB00979 | DRUGBANK_ID |
| D003519 | MESH_DESCRIPTOR_UI |
| 2905 | PUBCHEM_CID |
| 7153 | IUPHAR_LIGAND_ID |
| 266 | INN_ID |
| I76F4SHP7J | UNII |
| 225 | MMSL |
| 242 | MMSL |
| 39891 | MMSL |
| 4518 | MMSL |
| 001752 | NDDF |
| 004703 | NDDF |
| 372869004 | SNOMEDCT_US |
| 8348002 | SNOMEDCT_US |
| 83534009 | SNOMEDCT_US |
| 4018593 | VANDF |
| 4019700 | VANDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cyclomydril | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0065-0359 | SOLUTION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 19 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0395 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0396 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0397 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-096 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 12 sections |
| AK-PENTOLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-883 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 19 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-735 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-013 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 21 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3234 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3874 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4697 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 21 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-396 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 20 sections |